Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient

Mult Scler. 2016 Oct;22(12):1630-1631. doi: 10.1177/1352458516642032. Epub 2016 Apr 6.

Authors

Theoni Matoula¹, Vasiliki Nikolaou², Leonidas Marinos³, Serafeim Katsavos⁴, George Nasis⁵, Afroditi Economidi², Konstantina Karampidou², Alexander Stratigos², Christina Antoniou²

Affiliations

¹ A. Sygros' Hospital for Skin Diseases, University of Athens Medical School, Athens, Greece matoula_th@yahoo.gr.
² A. Sygros' Hospital for Skin Diseases, University of Athens Medical School, Athens, Greece.
³ Hematopathology Department, Evangelismos General Hospital, Athens, Greece.
⁴ Neurology Department, 251 Hellenic Air Force Hospital, Athens, Greece.
⁵ Neurology Department, Central Clinic of Athens, Athens, Greece.

PMID: 27053634
DOI: 10.1177/1352458516642032

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Fingolimod Hydrochloride / adverse effects*
Fingolimod Hydrochloride / therapeutic use
Humans
Lymphomatoid Papulosis / chemically induced*
Lymphomatoid Papulosis / diagnosis
Multiple Sclerosis / drug therapy
Skin Neoplasms / chemically induced*
Skin Neoplasms / diagnosis

Substances

Fingolimod Hydrochloride